Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor.

@article{Seghers2012SuccessfulRI,
  title={Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor.},
  author={A. C. Seghers and S. Wilgenhof and C. Lebb{\'e} and B. Neyns},
  journal={Melanoma research},
  year={2012},
  volume={22 6},
  pages={
          466-72
        }
}
  • A. C. Seghers, S. Wilgenhof, +1 author B. Neyns
  • Published 2012
  • Medicine
  • Melanoma research
  • The v-raf murine sarcoma viral oncogene homolog B1 (BRAF) gene is mutated at position 600 in about 50% of melanoma. Mutant BRAF activates the downstream effectors of the RAS-RAF-MEK-MAPK pathways and is a driver oncogene in these melanoma cells. Selective BRAF-V600 inhibitors (vemurafenib, dabrafenib) have high antitumor activity against BRAF-V600-mutant melanoma with objective tumor response rates. Resistance, however, develops within less than a year in the majority of patients. Several… CONTINUE READING
    Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma
    4
    Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
    98

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 27 REFERENCES